A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. Akebia Therapeutics, Inc. is down ~75% from its 2020 highs after its oral anemia candidate vadadustat failed to achieve safety non-inferiority versus standard of care in CKD-NDD patients. Log in to see them here or sign up to get started. The company traded as high as $3.18 and last traded at $3.07. Further, Akebia Therapeutics, Inc. (AKBA) has a beta value of 1.94, and an average true range (ATR) of 0.26. Have Watchlists? CAMBRIDGE - Akebia Therapeutics, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the Piper... | November 25, 2020 AKBA exchanged 5511687 shares on hands in most recent trading session and â¦ FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Find the latest press releases from Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue? Privacy Notice, and
All quotes are in local exchange time. Cookie Notice. Akebia Therapeutics, Inc. Common Stock (AKBA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho Sep. 4, 2020 at 6:22 a.m. Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the companyâs stock. Akebia Therapeutics, Inc. (NASDAQ:AKBA)âs Major holders. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Post-Market 0.02 (0.59%) Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Copyright © 2020 MarketWatch, Inc. All rights reserved. A number of [â¦] Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Simply Wall St. Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are â¦ If we look at who the major shareholders are, we find that insiders hold 3.18% of Akebia Therapeutics, Inc. shares while 78.98% of the shares are in the hands of institutional holders. We are a leader in the renal community â a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Fundamental company data and analyst estimates provided by FactSet. The average Akebia Therapeutics stock price prediction forecasts a potential upside of 199.88% from the current AKBA share price of $3.39. Barron's also provides information on historical stock ratings, â¦ Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Its products include Auryxia and Vadadustat. International stock quotes are delayed as per exchange requirements. Get Our PREMIUM Forecast Now, from ONLY $6.69! Do â¦ Akebia Therapeutics Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Get Akebia Therapeutics alerts: Shares of NASDAQ AKBA opened at $2.38 on Thursday. Is the Options Market Predicting a Spike in Akebia (AKBA) Stock? This browser is no longer supported at MarketWatch. Akebia Therapeutics (AKBA) Gets a Buy Rating from Mizuho Securities, Needham Releases a Buy Rating on Akebia Therapeutics (AKBA), Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates, Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release, Seth Klarman Axes Akebia Therapeutics Stake From Portfolio, Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session. Source: Kantar Media. Letâs start up with the current stock price of Akebia Therapeutics Inc. (AKBA), which is $3.15 to be very precise. Get Akebia Therapeutics Inc (AKBA:NASDAQ) real-time stock quotes, news and financial information from CNBC. AKBA, Akebia Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. Akebia Therapeutics. 8,047,847 shares traded hands during trading, an increase of 130% from the average session volume of 3,494,822 shares. Something went wrong while loading Watchlist.